Literature DB >> 10418852

Epidemiology of insulin resistance and its relation to coronary artery disease.

S M Haffner1.   

Abstract

The relation of insulin resistance to cardiovascular risk, particularly for coronary artery disease (CAD), has been well established in many prospective studies. The clustering of insulin resistance and/or hyperinsulinemia, hypertriglyceridemia, hypertension, and low HDL is now considered a feature of the insulin resistance syndrome. However, the association is complex and the pathways by which elevated insulin adversely affects both CAD risk factors and the risk of developing CAD have yet to be elucidated. Postprandial lipemia may be a mechanistic link between insulin resistance and CAD. Hyperinsulinemia appears to be a weak, but positive, independent cardiovascular risk factor. The strongest relations are seen in middle-aged rather than older persons and at higher elevations of plasma insulin levels. Individuals with type 2 diabetes have a risk of myocardial infarction (MI) equivalent to that of nondiabetic persons who have had a previous MI. Given the relatively weak association between duration of diabetes and severity of hyperglycemia and cardiovascular disease, common antecedents may underlie both CAD and type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10418852     DOI: 10.1016/s0002-9149(99)00351-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  37 in total

Review 1.  The metabolic syndrome and related cardiovascular risk.

Authors:  F Ramos; H P Baglivo; A J Ramírez; R Sánchez
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

Review 2.  Use of metformin in diseases of aging.

Authors:  John M Miles; Andrew D Rule; Barry A Borlaug
Journal:  Curr Diab Rep       Date:  2014-06       Impact factor: 4.810

Review 3.  Mechanisms for greater insulin-stimulated glucose uptake in normal and insulin-resistant skeletal muscle after acute exercise.

Authors:  Gregory D Cartee
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-10-20       Impact factor: 4.310

4.  Race differences in the relation of vitamins A, C, E, and β-carotene to metabolic and inflammatory biomarkers.

Authors:  Edward C Suarez; Nicole L Schramm-Sapyta
Journal:  Nutr Res       Date:  2013-10-14       Impact factor: 3.315

5.  Prior treatment with the AMPK activator AICAR induces subsequently enhanced glucose uptake in isolated skeletal muscles from 24-month-old rats.

Authors:  Kentaro Oki; Edward B Arias; Makoto Kanzaki; Gregory D Cartee
Journal:  Appl Physiol Nutr Metab       Date:  2018-03-08       Impact factor: 2.665

6.  Effects of Calorie Restriction and Fiber Type on Glucose Uptake and Abundance of Electron Transport Chain and Oxidative Phosphorylation Proteins in Single Fibers from Old Rats.

Authors:  Haiyan Wang; Edward B Arias; Carmen S Yu; Anthony R P Verkerke; Gregory D Cartee
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-11-09       Impact factor: 6.053

7.  Effects of Acute Exercise Combined With Calorie Restriction Initiated Late-in-Life on Insulin Signaling, Lipids, and Glucose Uptake in Skeletal Muscle From Old Rats.

Authors:  Kentaro Oki; Edward B Arias; Makoto Kanzaki; Gregory D Cartee
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2020-01-20       Impact factor: 6.053

Review 8.  Metformin: new understandings, new uses.

Authors:  Ripudaman S Hundal; Silvio E Inzucchi
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Renal dysfunction, metabolic syndrome and cardiovascular disease mortality.

Authors:  David Martins; Chizobam Ani; Deyu Pan; Omolola Ogunyemi; Keith Norris
Journal:  J Nutr Metab       Date:  2010-03-24

10.  Ankylosing spondylitis and other inflammatory spondyloarthritis increase the risk of developing type 2 diabetes in an Asian population.

Authors:  Hsin-Hung Chen; Su-Yin Yeh; Hue-Yong Chen; Cheng-Li Lin; Fung-Chang Sung; Chia-Hung Kao
Journal:  Rheumatol Int       Date:  2013-12-22       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.